All In Biotech

Drug Trial Radar · NCT05244551

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

A Phase 1, Open-Label Study of ABSK061 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

85

Planned (sponsor's estimate)

Start

Jun 30, 2022

Primary completion

Apr 30, 2025

Study completion Apr 30, 2025

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
Feb 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.

Conditions

  • Solid Tumor

Interventions

  • ABSK061Drug

    In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of DLTTime frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Incidence and severity of adverse events (AEs)Time frame: Through study completion, an average of half year

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Mary Crowley Cancer Research

    Dallas, Texas · Recruiting

  • Yuan LU

    Shanghai, Abbisko Therapeutics Co., Ltd. 12B Floor, Building 1, Lane 515, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Chongqing Daping Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Gongshu District, China · Recruiting

  • Sun Yat-sen Memorial Hospital/ the Second Affiliated Hospital of Sun Yat-sen University

    Guanzhou, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China · Not yet recruiting

  • Xuzhou Center Hospital

    Xuzhou, Jiangsu, China · Recruiting

  • First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • JILIN Cancer Hospital

    Changchun, Jilin, China · Not yet recruiting

  • Yunnan Cancer Hospital

    Yunnan, Kunming, China · Not yet recruiting

  • Liaoning Province Cancer Hospital

    Shenyang, Liaoning, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Sichuan, China · Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hanzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.